# A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects

> **NCT01161472** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 20 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 4mg fesoterodine
- **DRUG:** 8mg fesoterodine
- **DRUG:** alprazolam 1mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01161472
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2012-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01161472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01161472, "A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01161472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*